MedTrace Logo

Neutrolin Versus Heparin for Locking Hemodialysis Catheters

NCT03425448 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2019-03-05

No results posted yet for this study

Summary

Hemodialysis catheter related bacterial infections represent a major cause of mortality and morbidity in the hemodialysis population. Several locking agents had been tried with variable degree of success but not without side effects.

Neutrolin catheter locking agent comprises of heparin,citrate and trauolidine that had been studied in a prospective study in Germany, and it demonstrated a very good result in terms of reducing the catheter related infections and thrombosis.

This study is a multi-center, double-blind RCT comparing the hemodialysis catheter locking solution Neutrolin with heparin in reducing the rate of catheter related bacterial infection and thrombosis.

Conditions

  • Hemodialysis Catheter Infection
  • Catheter Thrombosis

Interventions

DRUG

Heparin

Heparin hemodialysis catheter lock solution

DEVICE

Neutrolin

Neutrolin hemodialysis catheter lock

Sponsors & Collaborators

  • King Abdullah International Medical Research Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-04
Primary Completion
2020-10-04
Completion
2021-04-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03425448 on ClinicalTrials.gov